Insider trading · Q3 2026 · CIK 1612940

ProQR Therapeutics N.V. (PRQR) insider trading.

In Q3 2026, insiders at ProQR Therapeutics N.V. reported 4 non-derivative transactions on 4 Forms 3, 4 and 5: 4 open-market purchases worth $1.1M and 0 sales.

Transactions
4
Purchases (P)
4
Sales (S)
0
Net shares, P minus S
650,000
Insiders
2
Last filed
2026-08-03

Insiders

InsiderRelationshipTransactionsBuysSales
de Boer Daniel AntonDirector, Officer · Chief Executive Officer330
Filius BartDirector110

Transactions

4 non-derivative rows, newest transaction first. Shares and prices as filed.
DateInsiderCodeSharesPriceOwned afterFiling
2026-07-31de Boer Daniel AntonP (A)200,000$1.77500,000Form 4
2026-07-17Filius BartP (A)150,000$1.72300,000Form 4
2026-07-09de Boer Daniel AntonP (A)150,000$1.74300,000Form 4
2026-07-07de Boer Daniel AntonP (A)150,000$1.59150,000Form 4

Transaction codes in this quarter

Get PRQR insider transactions through the API

Request with your API key
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=1612940&limit=100" \
  -H "Authorization: Bearer $SEC_API_KEY"

Insider trading API guide · PRQR company page · ProQR Therapeutics N.V. on SEC.gov

Questions

Are insiders buying or selling ProQR Therapeutics N.V. (PRQR)?

In Q3 2026, insiders at ProQR Therapeutics N.V. reported 4 non-derivative transactions on 4 Forms 3, 4 and 5: 4 open-market purchases worth $1.1M and 0 sales. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.

Where do these ProQR Therapeutics N.V. insider trades come from?

From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.

Source: SEC Insider Transactions Data Sets, Q3 2026, retrieved 2026-10-27. Footnotes, derivative holdings and amendments are in the linked filings. Not investment advice.

Plain-text version for agents and LLMs: /insider-trading/prqr.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.